Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Double-Masked, Randomized, Vehicle-Controlled Study to Evaluate the Effect of KPI-121 0.25% Ophthalmic Suspension on Signs and Symptoms of Inflammatory Meibomian Gland Disease

Next Previous
Trial Profile

A Phase II, Double-Masked, Randomized, Vehicle-Controlled Study to Evaluate the Effect of KPI-121 0.25% Ophthalmic Suspension on Signs and Symptoms of Inflammatory Meibomian Gland Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Loteprednol etabonate (Primary)
  • Indications Meibomianitis
  • Focus Therapeutic Use
  • Sponsors KALA BIO; Kala Pharmaceuticals

Most Recent Events

  • 02 Aug 2023 According to a Kala Pharamceuticals media release, Kala Pharamceuticals has changed its name to KALA BIO.
  • 19 Oct 2016 Status changed from active, no longer recruiting to completed.
  • 26 Feb 2016 Planned End Date changed from 1 Sep 2015 to 1 Aug 2016, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top